PGFC
PVLA

Peapack-Gladstone Financial Corp’s Palvella Therapeutics PVLA Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$898K Buy
5,875
+1,275
+28% +$155K 0.01% 423
2026
Q1 		$573K Buy
4,600
+1,600
+53% +$167K 0.01% 473
2025
Q4 		$314K Buy
+3,000
New +$256K ﹤0.01% 570

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Peapack-Gladstone Financial Corp's PVLA Position: Q2 2026 in Review

Peapack-Gladstone Financial Corp increased its Palvella Therapeutics (PVLA) stake by 28% in Q2 2026, buying an estimated $155K and bringing the position to 5,875 shares worth $898K. The position accounts for 0.01% of the portfolio, ranked #423.

Peapack-Gladstone Financial Corp first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Peapack-Gladstone Financial Corp held 5,875 shares of Palvella Therapeutics worth $898K as of Q2 2026.
  • Peapack-Gladstone Financial Corp bought 1,275 Palvella Therapeutics shares in Q2 2026, an estimated $155K.
  • Palvella Therapeutics made up 0.01% of Peapack-Gladstone Financial Corp's portfolio in Q2 2026, its #423 holding.
  • Peapack-Gladstone Financial Corp first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q2 2026, filed 14 Aug 2026.